Dr. Bernard Hamelin M.D. has more than 25 years of experience in France and abroad in the fields of clinical development and medical affairs at AstraZeneca and Sanofi pharmaceutical companies. In recent years, his work has focused on real-life health related data and digital platforms to accelerate research and clinical development and to improve the generation of evidence supporting the access and marketing of innovative molecules.
The convergence between recent discoveries in molecular and cellular biology and the digital transformation resulting from access to large amounts of health-related data has led pharmaceutical companies to revisit the planning and conduct of clinical studies. The use of these data has also made it possible to better communicate to health authorities and health care professionals the risks and benefits observed by patient sub-groups. Finally, the integration of data from various sources, such as the patient’s behaviors and preferences and the management of care systems has made it possible to develop more robust predictive models. Thanks to his experience and the links he has been able to create with institutional and private data providers and digital companies, Bernard is today considered as an expert by the industry of real-world data.
A member of the French National Society of Liver and Digestive diseases, Bernard Hamelin has acquired medical expertise in several other therapeutic areas such as immunology, oncology, rare diseases, respiratory and cardio-vascular diseases.
Morten completed his Master’s degree in Biotechnology at National University of Ireland, Galway, in 1997, specializing in Pharmacology. He joined Lundbeck in August 2020 as VP, Head of Clinical Operations.
Career to date Morten started at a CRO in 1997 as a CRA on an Epilepsy study. In the subsequent years he worked in CRO’s, consultancy and big Pharma taking on roles within Project Management, Program Oversight, Innovation and Strategic Partnerships. He joined Pfizer in 2003 and has a wide range of project management experience delivering projects across multiple therapeutic areas. From 2007 to 2011 he held a leadership role in Pfizer’s Clinical Study Management group providing Operational Oversight in various outsourcing models. As Group Lead of Emerging Markets and Established Products Business Units he managed a team of Program Directors in a variety of Therapy Areas from Phase II to Late Phase and Non-Interventional trials. From late 2011 Morten joined an Innovation technology CRO in the role of Senior Director and Head of Strategic Partnerships with the aim of improving Clinical Trial efficiencies and supporting Trial Sites. In August 2016 he joined InVentiv Health as VP, Head of Program Delivery in Neuroscience, before the group merged with INC to become Syneos Health.
Experienced medical affairs and market access leader – specific expertise in implementing patient centric care and service improvement initiatives. Member of EMEA Executive Leadership Committee of Medical Affairs Professional Society (www.medicalaffairs.org)
Strategic health planning in developed and developing markets
Wendi Carroll received her Pharm D from the University of the Pacific. She has 20+ years of diverse global experience in the biotechnology industry including roles within Clinical Development, Medical Affairs, and Risk Management. During her career she has advocated for critical partnerships with vendors supporting integration with internal stakeholders. Wendi is currently the Head of Global Medical Affairs Study Management at BioMarin Inc. where she oversees global operational strategy and execution for programs in the post-approval setting.
Disa has 15+ years of experience working in technology and innovation especially in the pharmaceutical industry. She is the Head of Integrated Clinical and Operational Analytics at Janssen Pharmaceutical Companies part of Johnson & Johnson. She was previously at UCB as the Head of Innovation and held other leadership roles. Prior to joining the pharma, she was a co-founder of an IT company. She has an EMBA and B.S. in Pharmaceutical Chemistry. In 2017, Disa started a consortium, a cross-industry collaboration on blockchain via PhUSE. Recently, she was awarded Top 100 Women in Technology, Financial Times top 100 most influential BAME Leader, and featured on the cover of CIO Look celebrating Women in Tech 2019. Her passion is on closing the gap for patients with unmet needs and exploring the right digital technologies to accelerate the implementation of end-to-end patient solution.
